A lack of appropriate in vitro models of three-dimensional lymph vessel growth hampers the study of lymphangiogenesis. We developed a lymphatic ring assay-a potent, reproducible and quantifiable three-dimensional culture system for lymphatic endothelial cells that reproduces spreading of endothelial cells from a pre-existing vessel, cell proliferation, migration and differentiation into capillaries. In the assay, mouse thoracic duct fragments are embedded in a collagen gel, leading to the formation of lumen-containing lymphatic capillaries, which we assessed by electron microscopy and immunostaining. We developed a computerized method to quantify the lymphatic network. By applying this model to gene-deficient mice, we found evidence for involvement of the matrix metalloproteinase, MMP-2, in lymphangiogenesis. The lymphatic ring assay bridges the gap between two-dimensional in vitro models and in vivo models of lymphangiogenesis, can be used to exploit the potential of existing transgenic mouse models, and rapidly identify regulators of lymphangiogenesis.
A lack of appropriate in vitro models of three-dimensional lymph vessel growth hampers the study of lymphangiogenesis. We developed a lymphatic ring assay-a potent, reproducible and quantifiable three-dimensional culture system for lymphatic endothelial cells that reproduces spreading of endothelial cells from a pre-existing vessel, cell proliferation, migration and differentiation into capillaries. In the assay, mouse thoracic duct fragments are embedded in a collagen gel, leading to the formation of lumen-containing lymphatic capillaries, which we assessed by electron microscopy and immunostaining. We developed a computerized method to quantify the lymphatic network. By applying this model to gene-deficient mice, we found evidence for involvement of the matrix metalloproteinase, MMP-2, in lymphangiogenesis. The lymphatic ring assay bridges the gap between two-dimensional in vitro models and in vivo models of lymphangiogenesis, can be used to exploit the potential of existing transgenic mouse models, and rapidly identify regulators of lymphangiogenesis.
Blood and lymphatic vessels form a contiguous system for the circulation of fluids and the delivery of molecules and cells within the body. Despite its implication in many pathologies such as lymphedema and cancer 1 , the lymphatic system has until recently been overshadowed by the greater emphasis placed on the blood vascular system. Understanding the molecular and cellular basis of the functional lymphatic abnormalities associated with different diseases is essential to develop new therapeutic strategies 2 .
The in vivo models of lymphangiogenesis include (i) induction of tumor-associated lymphangiogenesis by VEGF-C overexpression in tumor cells 3 or in transgenic mice 4 , (ii) lymphatic cell hyperplasia induced by intraperitoneal injection of incomplete Freund's adjuvant 5, 6 , (iii) lymphedema induced by the excision of a circumferential band of skin in mouse tail 7 or microsurgical ablation of tail lymph vessels 8 , and (iv) the corneal assay in which growth factor-containing pellets are implanted into corneal micropockets 9 . In addition to these mouse models, the Xenopus laevis tadpole has been recently described as a genetic model for the study of lymphangiogenesis 10 . One of the main limitations of using many of these models to identify key regulators of lymphangiogenesis is the involvement of inflammatory reactions, thus making discrimination between a direct effect on lymphatic endothelial cells and an indirect effect caused by the modulation of inflammatory mediators difficult.
Several lymphatic two-dimensional culture systems now available use human dermal lymphatic cells isolated by immunopurification by either fluorescence-activated cell sorting (FACS) or using magnetic beads 11 , and some use transformation with human telomerase reverse transcriptase 12 . Thoracic duct endothelial cells from different species are isolated by enzymatic digestion and can be cultured 13, 14 . Lymphatic endothelial cell cultures are also derived from lesions induced by injecting Freund's adjuvant into mice 5, 6 . In addition, lymphatic endothelial cell differentiation can be induced in embryoid bodies 15 . However, these systems suffer from several common drawbacks that include the limited number of cells that can be obtained by isolating non-transformed cells, the nonphysiological features of immortalized cells, and the putative dedifferentiation of cells in two-dimensional cultures. Moreover, none of these culture systems adequately recapitulate threedimensional growth of lymphatic microvessels with a lumen. An in vitro model that reproduces the different steps of lymphangiogenesis, including spreading from a pre-existing vessel, cell proliferation, migration and differentiation into capillaries, is therefore urgently needed to overcome these obstacles and gain new insights into the molecular mechanisms of lymphangiogenesis 2 .
The aortic ring assay is frequently used to investigate the molecular basis of angiogenesis [16] [17] [18] , to exploit the many available genetically modified mouse lines 17 , and to evaluate the pharmacological efficacy of pro-and anti-angiogenic agents 18 . In this study we adapted the aortic ring assay to the mouse thoracic duct. We describe a reproducible system for culturing lymphatic endothelial cell microvessels in three-dimensional lymphangiogenesis assays and a quantification strategy (Fig. 1a) . After we embedded fragments of mouse thoracic lymphatic ducts in a collagen gel, lymphatic capillaries formed from a single layer of endothelial cells with overlapping boundaries. The new lymphatic capillaries expressed specific markers of lymphatic vessels. We verified the absence of contaminating cells in the lymphatic network such as blood endothelial cells, fibroblasts, smooth muscle cells and inflammatory cells by whole-mount immunostaining. We validated these cultures as a model to study the mechanisms that underlie lymphangiogenesis, and to identify candidate genes and molecules involved in this process. The lymphatic ring assay bridges the gap between in vitro and in vivo studies and allows genetic analysis by using thoracic ducts from genetically modified mice. Using this assay we addressed the possibility that matrix metalloproteinases, which are recognized as important players in angiogenesis 19 , could modulate lymphangiogenesis. We provide evidence suggesting that MMP-2 is a regulator of lymphangiogenesis.
RESULTS

Establishment of the lymphatic ring assay
To develop three-dimensional lymphatic ring cultures, we excised thoracic ducts from mice. The thoracic duct can be identified by the intradermal injection of Evans blue (Fig. 1b) and distinguished from the aorta by immunopositivity for LYVE-1 (Fig. 1c,d ). We then dissected the thoracic duct and cut it transversely to generate lymphatic duct fragments, which we then embedded into type I collagen gels (Fig. 1a) . Five days later these lymphatic ring cultures exhibited outgrowth of cells that organized into capillary-like structures.
We developed a method to objectively quantify the lymphatic sprouts and their interconnected network by computer-assisted image analysis (Fig. 1a) . After image binarization, we determined the number of intersections of microvessels with a grid of concentric outlines of the thoracic duct boundary drawn by making successive dilations at similar intervals from the thoracic duct boundary (Fig. 2a) .
Addition of serum stimulated outgrowth in a dose-dependent manner, and we never detected outgrowth in the absence of serum (Fig. 2a) . Incubation of lymphatic rings in a physiologically relevant atmosphere (5% O 2 ) significantly accelerated capillary formation (P o 0.05). Although we observed no difference between vessel outgrowth under 5% O 2 and 21% O 2 during the first week of culture, improvement of lymphatic vessel outgrowth in 5% O 2 started on day 9 and continued until the end of the assay (P o 0.05). From day 7 to day 9, these vessels became progressively more interconnected as demonstrated by the progressive displacement from the explant of the maximal number of endothelial cells (Fig. 2b) . In addition, the percentage of outgrowing explants increased under 5% O 2 condition, reaching 87% ± 4.5% in low O 2 atmosphere and 55% ± 6% under ambient oxygen culture (Fig. 2c) . For all subsequent assays, we cultured lymphatic rings in these defined optimal conditions (10% FCS and 5% O 2 ).
Presence of typical features of lymphatic vessels
Immunochemical characterization of cells growing out from thoracic duct rings revealed positive staining for LYVE-1 (Fig. 3a) and VEGFR-3 ( Fig. 3b) , two markers of lymphatic vessels 2 . Cells were positive for Von Willebrand factor ( Supplementary Fig. 1 online) , supporting their endothelial origin. Cells were negative for markers of other cell types such as blood endothelial cells (CD34), fibroblasts (Thy1.1) and inflammatory cells (CD45) ( Supplementary  Fig. 1 ). Less than 15% of spreading cells, probably smooth muscle cells, were positive for alpha smooth muscle actin (aSMA; Supplementary Fig. 1 ). However, none of these cells covered the lymphatic capillaries; they were localized around the rings and did not participate in the structure of the vascular network. Therefore, despite the fact that the starting material contained different cell Analysis by transmission electron microscopy revealed microvessels composed of a single layer of endothelial cells delimiting a lumen (Fig. 3c,d ). Intercellular junctions were formed by simple abutment of apposing endothelial cells or by interdigitation of endothelial cell margins (Fig. 3e ). These endothelial cells had overlapping boundaries without well-established adhesive junctions but with occasional tight junctions ( Fig. 3f ) and contained Weibel palade bodies (Fig. 3g) . The lymphatic endothelial cells also displayed a polarized organization characterized by a regular abluminal surface apposed to the surrounding matrix and cell processes extending into the lumen on the luminal side (Fig. 3c) . Therefore, capillary lumen can be distinguished from collagen degradation observed between juxtaposed cells (Fig. 3c ). All these features are typical of lymphatic vessels 20 .
Sensitivity to lymphangiogenic factors
We validated the lymphatic ring assay as a model for lymphangiogenesis by evaluating the impact of a well-recognized lymphangiogenic factor (VEGF-C) 2 on lymphatic endothelial cell outgrowth. As VEGFs are present in serum, we supplemented the culture medium with a chemically defined serum (Ultroser G) at a concentration of 4%, instead of FCS. The basal level of lymphatic cell sprouting observed under these conditions was improved by adding VEGF-C to the medium (2.7-fold improvement at the optimal concentration of 10 ng/ml; P o 0.05; Fig. 4a and Supplementary Fig. 2 online) . Furthermore, a soluble form of VEGFR-3 inhibited the induction of microvessel outgrowth by VEGF-C (P o 0.05; Fig. 4b ). MAZ51, an inhibitor of ligand-induced VEGFR-3 autophosphorylation 21 , also reduced serum-dependent lymphatic outgrowth (52% reduction at the optimal concentration; P o 0.05; Fig. 4c ).
Suitability to screen for lymphangiogenic factors
To identify other lymphangiogenic factors, we tested recombinant growth factors in the lymphatic ring assay under serum-free conditions in the presence of 4% Ultroser G. We first tested placental growth factor-1 (PlGF-1), a member of the VEGF family, and fibroblast growth factor-2 (FGF-2), which have both been implicated in pathological angiogenesis (Fig. 4d,e and Supplementary Fig. 3 online) . Although both factors used at 5 ng/ml slightly increased lymphatic cell outgrowth, this increase was not statistically significant (P 4 0.05), and higher concentrations did not affect lymphatic endothelial cell outgrowth (Fig. 4d,e) . In agreement with these results, suramin, a polysulfonated naphthylurea that binds to and inhibits FGF 22 , was unable to inhibit lymphatic outgrowth in 10% FCS lymphatic ring cultures (Fig. 4f) . In sharp contrast, the homodimeric platelet-derived growth factor-BB (PDGF-BB) at 5 ng/ml induced a threefold increase in lymphatic vessel formation (P o 0.05) ( Fig. 4g and Supplementary Fig. 3 ). These data support previous studies reporting a lymphangiogenic effect of PDGF-BB. PDGF-BB has been shown to induce intratumoral lymphangiogenesis and lymphatic metastasis in vivo and to stimulate lymphangiogenesis in corneal assays 9, 23 . An inhibitor of the PDGF receptor abrogated lymphatic cell outgrowth stimulated by 5 ng/ml PDGF (P o 0.05; Fig. 4h ) and reduced serum-induced lymphangiogenesis in a dose-dependent manner (59% reduction at 3.5 mg/ml; P o 0.05; Fig. 4i ). Cell viability assays at the end of the experiment showed that this inhibitor did not exert a toxic effect. 
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Together these data show that PDGF-BB, but not PlGF-1 or FGF-2, is a lymphangiogenic factor acting directly on lymphatic endothelial cells. We next addressed the possibility that some factors could indirectly affect lymphangiogenesis by inducing the release of lymphangiogenic factors from the few smooth muscle cells present in the culture. We cultured smooth muscle cells in vitro with FGF-2 or PlGF-1 (10 ng/ml). The resulting medium conditioned by smooth muscle cells treated with FGF-2 or PlGF-1 increased the lymphangiogenic response in the lymphatic ring assay as compared to medium conditioned by untreated smooth muscle cells (Supplementary Fig. 4 online) . This clearly indicates that both PlGF-1 and FGF-2 can stimulate lymphangiogenesis indirectly by promoting a smooth muscle cell-mediated effect. However, we did not observe such an indirect effect on smooth muscle cells in the lymphatic ring cultures (Fig. 4d,e) demonstrating that in this assay, smooth muscle cells are in limited amount or are not sensitive to stimulator.
Analysis of proteases implicated in lymphangiogenesis
A major potential application of the lymphatic ring model is the use of thoracic ducts derived from genetically modified mice to assess the role of candidate genes in lymphangiogenesis. As we have previously demonstrated that PAI-1 deficiency impairs blood endothelial cell migration from aortic rings 24 , we investigated +10 ng/ml VEGF-C 5 ng/ml 1 µg/ml 3 µg/ml 9.5 µg/ml 16 µg/ml 5 µg/ml 4% Ultroser +5 ng/ml PDGF 0.35 µg/ml 3.5 µg/ml 1.7 µg/ml 7 µg/ml 3.5 µg/ml 10 ng/ml 5 ng/ml 10 ng/ml 20 ng/ml 4% Ultroser 5 ng/ml 30 mg/ml 60 mg/ml 10 ng/ml 20 ng/ml . Quantification was performed by computerized analysis and curves were normalized as described in Methods. Each curve is a mean microvessel distribution curve obtained by averaging the 5 individual distributions generated for each experimental condition (n ¼ 5). A Student's t-test is used to determine the statistical differences between control distribution curve and curves of experimental conditions. *P o 0.05; NS, not significant.
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whether PAI-1 has a similar role in lymphangiogenesis. Lymphatic cell outgrowths were equivalent from thoracic duct fragments derived from Serpine1 -/-(also known as PAI-1 À/À ) mice or wildtype littermates (Fig. 5a and Supplementary Fig. 5 online) . Moreover, aprotinin, a serine protease inhibitor, did not impair lymphangiogenesis in these assays (Fig. 5b) . These results indicate that PAI-1 is dispensable for migration and outgrowth of lymphatic endothelial cells, in contrast to its important role in angiogenesis.
To assess the putative role of metalloproteinases in lymphangiogenesis, we first examined whether matrix metalloproteinases are present in the conditioned medium from lymphatic ring assays (Fig. 5) . Gelatinolytic zymographic analysis revealed the presence of two pro-MMP-2 species 25 without any active form, which are likely produced by the lymphatic cells (Fig. 5f ). MMP-2 activation likely occurs at the cell surface in the collagen matrix and is thus not detectable in the supernatant. TIMP-2, a physiological inhibitor of matrix metalloproteinases, induced a dose-dependent decrease in lymphatic network formation (55% reduction at 1 mg/ml; P o 0.05; Fig. 5c ). RO-28-2653, a synthetic inhibitor targeting mainly Mmp-2, MMP-9 and MMP-14 18 , inhibited lymphatic vessel outgrowth (P o 0.05; Fig. 5d) . Notably, thoracic duct rings derived from Mmp2 À/À mice exhibited impaired lymphangiogenesis in comparison to those from wild-type mice (Fig. 5e) . To validate these observations in an in vivo model, we intraperitonealy injected Mmp2-deficient mice with incomplete Freund's adjuvant to induce lymphangioma. White benign tumors composed of lymphatic cells 5, 6 grew on the surface of diaphragm and liver in both genotypes. However, we observed a significant reduction of the surface of the lesions developed on diaphragm and liver in the absence of MMP-2 (n ¼ 7; P ¼ 0.029, P ¼ 0.002, respectively; Supplementary Fig. 6 online) . Together, these data establish MMP-2 as a potentially important effector of lymphangiogenesis.
DISCUSSION
In vitro two-dimensional cultures using isolated lymphatic endothelial cells are useful assays for studying cell proliferation 11 . In addition, tube forming assays on a threedimensional matrix 5 or in embryoid bodies 15 are very potent models to investigate cell migration and tube-like structure formation. However, tube formation in these assays reflects the capacity to generate a complex plexus similar to that observed during embryogenesis 26 and therefore mimics vasculogenic processes rather than lymphangiogenesis, which is defined as the formation of new lymphatic vessels from pre-existing ones. The lymphatic ring assay that we developed has the advantage of recapitulating different steps of lymphangiogenesis, including endothelial cell sprouting from an existing vessel, migration and differentiation into capillaries. However we note that, although it is the prevailing view that sprouting of endothelial cells from preexisting vessels is one of the mechanisms by which new lymphatic vessels grow in adults, this has not to date been demonstrated from the adult thoracic duct in vivo.
Studies in three-dimensional cultures are often hampered by difficulties in achieving objective and reproducible quantification. Many quantification strategies are based on the manual processing of images, which is time-consuming and subjective 27 . To overcome this limitation, we designed a computer-assisted method of image analysis to quantify objectively the outgrowth and connectivity of the lymphatic vascular network. We validated the culture model and its computerized quantification by testing well-known regulators of lymphangiogenesis and angiogenesis. The involvement of the VEGF-C/VEGFR-3 pathway 2 was supported by stimulation of lymphatic endothelial cell outgrowth by VEGF-C, and its inhibition by a soluble form of VEGFR-3 or by MAZ51, which blocks ligandinduced VEGFR-3 autophosphorylation 21 . In our system, PlGF-1 or FGF-2 did not affect lymphatic capillary formation. Accordingly, suramin, an FGF trapping molecule 22 , did not inhibit serumstimulated lymphangiogenesis. Therefore, PlGF-1 and FGF-2 do not directly control lymphatic endothelial cell outgrowth and are not sufficient per se to promote sprouting from pre-existing vessels. PlGF-1 (ref. 28) and FGF-2 probably exert lymphangiogenic effects in vivo indirectly by promoting the release of pro-lymphangiogenic factors by accessory cells. For instance, FGF-2 influences lymphatic cell growth in mouse cornea assays by promoting VEGF-C secretion from blood vascular endothelial cells 29 .
Our data confirmed the lymphangiogenic activity of PDGF-BB 9, 23 , which could be abrogated by an inhibitor of PDGF receptor tyrosine kinase. Notably, blockade of the PDGF receptor was sufficient to inhibit serum-stimulated lymphatic outgrowth. This identified PDGF as a potent serum-derived lymphangiogenic factor. A major potential application of the lymphatic ring assay is the investigation of the impact of gene deficiency on lymphangiogenesis through the exploitation of genetically modified mice. As proof of principle we examined the role of proteases and their inhibitors in lymphangiogenesis. Although PAI-1 is essential for blood endothelial cell migration in the aortic ring assay 24 , we obtained evidence that PAI-1 is dispensable for lymphatic endothelial cell outgrowth. In contrast, lymphangiogenesis was reduced by physiological MMP inhibitor and a broad-spectrum synthetic MMP inhibitor. Lymphangiogenesis was also impaired by the specific targeted deletion of Mmp2, but blood endothelial cell outgrowth in the aortic ring assay was not affected in Mmp2 À/À mice 19 . Although the contribution of MMPs in general to lymphangiogenesis has been suggested through the use of broad spectrum inhibitors 6 , our study suggests that MMP-2 is a regulator of this process. These data are consistent with the kinetics of MMP-2 production observed in a lymphangiogenic model of adult skin regeneration in which MMP-2 expression closely correlates with lymphatic endothelial cell infiltration 7 . The implication of MMP-2 in lymphangiogenesis is further supported, in vivo, by the impaired formation of lymphangioma in deficient mice. By identifying PAI-1 as dispensable and MMP-2 as indispensable factors for lymphangiogenesis, we demonstrated that the lymphatic ring assay is a powerful tool for delineating the difference between molecular mechanisms underlying angiogenesis and lymphangiogenesis.
In conclusion, the lymphatic ring assay is an innovative system for the three-dimensional cultivation of mouse lymphatic microvessels. This system allows (i) identification of new candidates that regulate post-natal growth and maintenance of lymphatic vasculature, (ii) screening for pro-and anti-lymphangiogenic agents, (iii) exploitation of genetically modified mice, and (iv) identification of specific mechanisms that underlie lymphangiogenesis or angiogenesis. The combination of this model with computerized quantification offers unprecedented potential for gaining new insight into lymphangiogenesis, with important prospects for the design of strategies to manipulate the lymphatic system and thereby counteract diseases such as metastatic cancer and lymphedema.
METHODS
Thoracic duct collection and three-dimensional lymphatic ring cultures. To learn to locate the thoracic duct and to set up the assay, we identified thoracic ducts by intradermal injection of Evans blue (1.5% in phosphate-buffered saline; pH 7.4 ) into the paws and ears of donor mice before killing them (Fig. 1b) . Subsequently, for routine assays, Evans blue staining was not required, and we dissected mice without staining ( Supplementary  Fig. 7 online) . To facilitate dissection, we cultured thoracic ducts from male and female C57Bl/6J mice, preferably 2-4 months of age. However, 1-month-old mice can also be used. We used the previously described PAI-1-deficient mice (PAI-1 À/À ) 24 , MMP-2-deficient mice (Mmp2 À/À ) 19 and the corresponding wild-type mice. All experiments using live mice were approved by the local ethics committee of the University of Liège.
We prepared cylindrical agarose wells before killing mice and excising lymphatic ducts 16, 17, 30 . We poured heated, sterile 1.5% type VII agarose solution (Sigma-Aldrich; 25 ml/dish) into 100-mm culture dishes (BD Falcon), and allowed the solution to solidify at 4 1C. We prepared agarose cylinders by punching two concentric circles in the agarose with punchers of 10-and 17-mm diameter and transferred them to a 86 Â 12-mm bacterial Petri dish (Nunc). We obtained thoracic ducts by microsurgery using very thin microdissecting forceps and Vannas scissors (Supplementary Fig. 7) . First, we carefully dissected the periaortic fibroadipose tissue (step 1; Supplementary Video 1 online). Then we removed fat tissue surrounding the lymphatic ring and taking care not to damage the lymphatic wall (step 2; Supplementary Videos 2 and 3 online). During this dissection, we continuously filled with sterile phosphate-buffered saline (pH 7.4) the thoracic cavity bounded by the rib cage and the intact diaphragm. After cutting thoracic ductedges (step 3; Supplementary Video 4 online), we immediately transferred the duct to a culture dish containing ice-cold serum-free MEM medium (Invitrogen) and cut the duct into 1 mm-long rings (about 10 pieces per duct; Supplementary Fig. 7) . We then embedded ring-shaped explants between two layers of type I collagen gel polymerized in cylindrical agarose wells prepared as described above. We obtained collagen gels by mixing 7.5 volumes of collagen R (2 mg/ml; Serva Electrophoresis) with 1 volume of 10Â MEM (Gibco), 1.5 volumes of NaHCO 3 (15.6 mg/ml) and approximately 0.1 volume of NaOH (1 M) to adjust pH 7.4. We maintained 4 gels, each one containing a lymphatic duct ring, in a culture dish with 6 ml of MCDB131 (Invitrogen) supplemented with 25 mM NaHCO 3 , 10% FCS (Gibco) or 4% Ultroser G (BioSepra), 1% glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. We kept cultures at 37 1C in a humidified incubator (HERAcell 150; Heraeus) under ambient (21% O 2 , 5% CO 2 , 74% N 2 ) or reduced oxygen conditions (5% O 2 , 5% CO 2 and 90% N 2 ). We used autologous mouse serum (3%) to maintain lymphatic ring cultures derived from PAI-1 À/À , Mmp2 À/À mice or their wild-type counterparts.
Treatment with growth factors and inhibitors. We prepared lymphatic rings as indicated above and maintained them in MCDB131 medium supplemented with either 4% Ultroser G or 10% FCS. We added the following factors to the culture medium at the beginning of the experiment as appropriate: recombinant mouse VEGFR-3/Fc chimera (sVEGFR-3; R&D Systems), human placental growth factor-1 (hPlGF-1; R&D Systems), human fibroblast growth factor-2 (hFGF-2; R&D Systems), suramin (SigmaAldrich), human platelet-derived growth factor BB (hPDGF-BB; R&D Systems), PDGF receptor tyrosine inhibitor II (Calbiochem) and aprotinin (Roche). VEGF-C, MAZ51, Ro-28-2653 and rTIMP-2 have been described previously 18 . We used a Viability/Cytotoxicity kit (Molecular Probes) according to manufacturer's instructions to assess the potential toxic effects of these compounds.
Quantification of lymphangiogenesis. We collected images for analysis under identical conditions of light, contrast and magnification. We kept processing parameters constant to allow automatic image processing. We obtained binary images in a two-step procedure as described previously 27 and illustrated in Supplementary Figure 8 online. We determined the number of intersections of microvessels with a grid of concentric rings drawn by making successive dilations at similar intervals of the thoracic duct boundary. We determined the number of intersections between microvessels and this grid for each image. Microvessel distribution is defined as the number of intersections plotted as a function of
